publications

Publish innovative results and secure attention.

Related to the topic, you will find a selection of articles that have been published in international journals with peer-review by the company's founder as initiator.

From an idea to worldwide approval.

For products that have already received market approval, we carry out clinical studies in which the medical benefits and safety of the products are presented. We will publish the study results with you in international high-ranking journals and help you to ensure that your product is reimbursable by health insurance companies (see also list of aids). Our customers use the study results to market their medical device efficiently.

We recently demonstrated the benefits and safety of a standing stand in an international retrospective clinical evaluation. The publication is received very positively by the research community and is used efficiently by our customer to market the medical device. We also successfully published the results of a prospective study of a novel non-invasive medical device with which patients with an increased cardiovascular risk profile lost weight over a long period of time (over 2 years).

List of publications
  • Schmidt-Lucke C, Käferle J, Rydh Berner BM, Ahlborg L, Hansen HM, Skjellvik Tollefsen U, Thon T, Damkjær Moen R, Pekanovic A, Tornberg AB, Lauruschkus K. Effect of assisted walking movement in patients with genetic and acquired neuromuscular disorders with the motorised Innowalk device: an international case study meta-analysis. PeerJ. 2019
  • by Seck P, Sander FM, Lanzendorf L, by Seck S, Schmidt-Lucke A, Zielonka M, Schmidt-Lucke C. Persistent Weight Loss with a Non-Invasive Novel Medical Device to Change Eating Behavior In Obese Individuals With High-risk Cardiovascular Risk Profile. PLoS ONE. 2017

From the patient to the laboratory and back to the clinic.

Translational studies answer questions that concern our patients, on the border between basic research and practical application. Curiosity, accuracy, precise and well-founded knowledge and a feeling for a relevant current issue characterize academic research with practical applicability. The regeneration of vessels is decisively influenced by cells circulating in the bloodstream and is the basis for proper organ function. These works have been quoted and reproduced many times internationally.

List of publications
  • Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation. 2005
  • Fichtlscherer S, Schmidt-Lucke C, Bojunga S, Rossig L, Heeschen C, Dimmeler S, Zeiher AM. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy. Eur Heart J. 2006
  • Schmidt-Lucke C, S Fichtlscherer, A Aicher, C Tschope, H-P Schultheiss, A M Zeiher, S Dimmeler. Quantification of circulating endothelial progenitor cells using the modified ISHAGE protocol. PLoS ONE. 2010
  • Schmidt-Lucke C, Stephan Fichtlscherer, Lothar Rössig, Ulrike Kämper, Stefanie Dimmeler. Improvement of endothelial damage and regeneration indexes in patients with coronary artery disease after 4 weeks of statin therapy. Atherosclerosis. 2010
  • GP Fadini, Maruyama S, Ozaki T, Taguchi A, Meigs J, Dimmeler S, Zeiher A, de Kreutzenberg S, Avogaro A, Nickenig G, Schmidt-Lucke C, Werner N. Circulating Progenitor Cell Count for Cardiovascular Risk Stratification. A pooled analysis. PLoS ONE. 2010

Breaking new ground. Think unusually. Free from conventions.

The human parvovirus B19 (B19V) usually only causes a self-limiting disease. In rare cases, the disease is fatal. B19V is the pathogen that is most commonly associated with an inflammatory heart muscle disease, inflammatory cardiomyopathy. The pathogen infects vasoregenerating cells (endothelial precursor cells), which leads to vascular damage and subsequent reduced blood flow to an organ. For the first time, we are showing a treatment approach to reduce B19V-induced vascular damage by protecting precursor cells. This approach forms the basis for developing an effective B19V therapy.

List of publications
  • Schmidt-Lucke C, Zobel T, Escher F, Tschöpe C, Lassner D, Kühl U, Gubbe K, Volk HD, Schultheiss HP. Human Parvovirus B19 (B19V) Up-regulates CXCR4 Surface Expression of Circulating Angiogenic Cells: Implications for Cardiac Ischemia in B19V Cardiomyopathy. J Infect Dis. 2018
  • Schmidt-Lucke C, Spillmann F, Bock T, Kühl U, Van Linthout S, Schultheiss HP, Tschoepe C. Interferon-beta modulates endothelial damage in patients with cardiac persistence of parvovirus B19. J Infect Dis. 2010
  • Pozzuto T, by Kietzell K, Bock T, Schmidt-Lucke C, Poller W, Zobel T, Lassner D, Zeichhardt H, Weger S, Fechner H. Transactivation of human parvovirus B19 gene expression in endothelial cells by adenoviral helper functions. Virology. 2011
  • Schmidt-Lucke C, Escher F, Van Linthout S, Kuehl U, Miteva K, Ringe J, Sable T, Schultheiss HP, Tschoepe C. Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy. Mediators Inflam. 2015
  • Schmidt-Lucke C, Sable T, Schrepfer S, Kühl U, Wang D, Bell K, Beaker PM, Fechner H, Pozzuto T, Van Linthout S, Lassner D, Spillmann F, Holinski S, Volk HD, Schultheiss HP, Tschöpe C. Impaired endothelial regeneration through human parvovirus B19-infected angiogenic cells in cardiomyopathy. J Infect Dis. 2015
  • Sable T, Bock CT, Kühl U, Rohde M, Lassner D, Schultheiss HP, Schmidt-Lucke C. Telbivudine Reduces Parvovirus B19-Induced Apoptosis in Circulating Angiogenic Cells. Viruses. 2019

Change policies.

The ACE study was an investigator-initiated study with the aim of expanding the indication of enoxaparin. In this randomized, prospective multicenter trial, enoxaparin was not inferior to unfractionated heparin and phenprocoumon in TOE-assisted cardioversion of persistent atrial fibrillation.

List of publications
  • Schmidt-Lucke C, Couple WD, Stellbrink C, Nixdorff U, Hofmann T, Meurer J, Grewe R, Daniel WG, Hanrath P, Mugge A, Klein HU, Schmidt-Lucke YES. Quality of anticoagulation with unfractionated heparin plus phenprocoumon for the prevention of thromboembolic complications in cardioversion for non-valvular atrial fibrillation. Sub-analysis from the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Thromb Res. 2007
  • Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke YES. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the anticoagulation in cardioversion using enoxaparin (ACE) trial. Circulation. 2004
  • Stellbrink C, Nixdorff U, Hofmann T, Lehmacher W, Daniel WG, Hanrath P, Geller C, Mugge A, Sehnert W, Schmidt-Lucke C, Schmidt-Lucke YES. Use of subcutaneous enoxaparin compared to intravenous heparin and oral phenprocoumon in the setting of cardioversion — the ACE study (anticoagulation in cardioversion using enoxaparin). Card Electrophysiol Rev. 2003
  • Harmful PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, Brecht JG. Economic evaluation of enoxaparin for anticoagulation in early cardioversion of persisting nonvalvular atrial fibrillation: a statutory health insurance perspective from Germany. At J Cardiovasc Drugs. 2007

Profound knowledge in theory and practice — book contributions

Recognition in the professional world.


Harrison's Internal Medicine is a very renowned, comprehensive work in Germany that reflects the highest quality standards in medicine. The standard work in the Anglo-American region has enjoyed undisputed trust since 1950. The 17th and 18th editions of this encyclopedia of human medicine were updated by 300 specialists in their fields and were adapted to German diagnostic and treatment standards. Two innovative chapters on stem cell biology and applications in clinical medicine were entrusted to the founder's expertise in two consecutive editions.

List of publications
  • Schmidt-Lucke C. Regenerative Medicine, Stem Cell Biology, and Applications of Stem Cell Biology in Clinical Medicine, in Harrison 18th edition; ABW, 2016
  • Schmidt-Lucke C. Regenerative Medicine, Stem Cell Biology, and Applications of Stem Cell Biology in Clinical Medicine, in Harrison 18th edition; ABW, 2012
  • Schmidt-Lucke C. Regenerative Medicine, Stem Cell Biology, and Applications of Stem Cell Biology in Clinical Medicine, in Harrison 17th edition; ABW, 2009

Die Digitalization of the healthcare market This will probably only be revolutionized by the introduction of antibiotics. Medical apps are increasingly influencing our behavior. Despite a huge number of medical apps, only a very small number have proven their benefits or comply with the strict German and European regulations for a medical device. We provide support and services for developers and companies who want to take on the challenges of this disruptive technology.

List of publications
  • Schmidt-Lucke C. Medical apps between lifestyle and medical device. Going public, 2016.
  • Schmidt-Lucke C. Founding with a medical app. Starting up, 2017.

With over 1000 questions from the Pharmacology in the field of internal medicine and cardiology, students can specifically prepare for their oral exams. The effective way to always have the right answer Modern learning techniques to learn the extensive material for the exam and to have it ready to treat the patient!

List of publications
  • Aicher A, Eagle K, Schmidt-Lucke C and Brenner W. Pharmacology in question and answer. Urban & Fischer Verlag, Munich — Jena, 2005

Principles and Practice of Panvascular Medicine by editors Peter Lanzer and Eric J. Topol includes the areas of cardiology, heart surgery, vascular surgery, radiology, neurology, neurosurgery and vascular medicine. This provides interdisciplinary and holistic perspectives of modern vascular medicine. Young colleagues and specialists are addressed. The founder was entrusted with the basic content of vascular medicine.

List of publications
  • Schmidt-Lucke C. Peripheral Artery Physiology and Pathophysiology: Special Considerations, in: Principles and Practice of Panvascular Medicine (eds. Lanzer P, Topol E), Springer-Verlag, Heidelberg-New York, 2002
  • Schmidt-Lucke C. Microperfusion disorders in peripheral arterial disease. Med Welt 53:206 —10, 2002

Demonstrate the medical benefits of your product

With our many years of experience and expertise, we offer effective solutions to demonstrate the medical benefits of your product.

From the conception to the execution of preclinical and clinical investigations, we support you with customized services.

Find out how MEDIACC can help you achieve reimbursability for your products.